UK trumpets life sciences post-Brexit ‘sector deal’

The UK government has secured commitments from 25 international organisations that it says will ensure the country remains a pharma hub after it leaves the EU. MSD, GSK and AstraZeneca projects were highlighted, as well as a $100m contract from The Medicines Company to test a cholesterol-lowering drug at the University of Oxford’s clinical trials unit, a £40m investment from Seqirus to build a fill-and-finish vaccine plant in Liverpool and an initiative between Janssen and the University of Oxford to find novel clinical trial approaches for mental health disorders